In preclinical studies, LRRK2 inhibition through an antisense oligonucleotide (ASO) approach leads to reduction in both LRRK2 protein and alpha-synuclein inclusions and it has also been translated in a Phase 1 clinical trial evaluating increasing ASO doses administered via intrathecal injections in patients with PD which has been completed in August 2024 (NCT03976349). Here, SNCA is linked to Parkinson disease.